Research
Cerebrolysin — living evidence map
The Atlas page holds the claims; this is how its evidence evolved.
Summary
Cerebrolysin is a neuropeptide preparation described as mimicking the action of endogenous neurotrophic factors on brain protection and repair; it is a preparation, not a single molecule. · pmid:22514792
Mechanism
In dementia models it decreased beta-amyloid deposition and tau phosphorylation and increased synaptic density; in stroke models it reduced infarct volume and promoted functional recovery. · pmid:22514792
History
A 2018 meta-analysis of nine randomized ischemic-stroke trials (1,879 patients) reported greater early neurological improvement with Cerebrolysin than placebo, and described it as a parenterally administered preparation approved for stroke treatment. · pmid:29248999
In the CARS trial, 21 days of Cerebrolysin alongside rehabilitation, started 24 to 72 hours after stroke, improved arm motor function at day 90 compared with placebo. · pmid:26564102
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Proportion of the 3 claims about Cerebrolysin standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
3 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Cerebrolysin yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
- Approved-label dose · a resolved regulatory document names a labelled dose
nothing resolved on this rung
- Studied human doses · resolved human studies at the established tier
nothing resolved on this rung
- Observational evidence · resolved human data at the emerging tier: thin, or contested
- Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. · pmid 26564102 · 2016
- Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. · pmid 29248999 · 2018
- Community-reported protocols · protocol propositions from distinct members, counted once per human
nothing resolved on this rung
- Preclinical evidence · resolved animal, cell or mechanistic work
- The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. · pmid 22514792 · 2012
3 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.